Sinovac Biotech Ltd (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, hand foot and mouth disease (HFMD), seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza, coronavirus, pneumococcus, poliomyelitis, varicella and mumps. The Company's pipeline consists of vaccine candidates in the clinical and pre-clinical development Phases in China. The Company is engaged in the sales, marketing, manufacturing and development of vaccines for infectious disease. The Company develops various products, including Healive, Bilive, Anflu, Panflu Whole Viron Pandemic Influenza Vaccine, Split Viron Pandemic Influenza Vaccine, Panflu.1, Mumps Vaccine, Enterovirus 71 (EV71) Vaccine, Pneumococcal Polysaccharide Vaccine, Pneumococcal Conjugate Vaccine.
公司代碼SVA
公司名稱Sinovac Biotech Ltd
上市日期Nov 13, 2009
CEOYin (Weidong)
員工數量3037
證券類型Ordinary Share
年結日Nov 13
公司地址No. 39 Shangdi Xi Road
城市BEIJING
上市交易所NASDAQ OMX - NASDAQ BASIC
國家China
郵編100085
電話861082890088
網址http://www.sinovac.com/
公司代碼SVA
上市日期Nov 13, 2009
CEOYin (Weidong)